Dorsomorphin (Compound C): Robust Solutions for AMPK & BM...

Researchers tackling cell viability, proliferation, or cytotoxicity assays frequently encounter inconsistent outcomes, especially when dissecting complex metabolic and signaling pathways like AMPK and BMP/Smad. Common pain points—such as variable ACC phosphorylation readouts or unpredictable autophagy responses—can undermine the reliability of both mechanistic and translational studies. Dorsomorphin (Compound C) (SKU B3252) has emerged as a cornerstone reagent for these scenarios, offering high selectivity as an ATP-competitive AMPK inhibitor and BMP signaling antagonist. This article distills best practices for leveraging Dorsomorphin, addressing real-world laboratory challenges and integrating the latest quantitative data to enhance reproducibility and confidence in signaling pathway investigations.

What is the underlying principle that enables Dorsomorphin (Compound C) to dissect both metabolic and differentiation pathways?

In many translational research projects, scientists need to simultaneously interrogate metabolic regulation and cell fate decisions—such as linking AMPK-driven autophagy to BMP-mediated differentiation. However, most inhibitors lack the dual selectivity or clarity of action required to untangle these interconnected pathways, leading to ambiguous data.

Dorsomorphin (Compound C) operates as a highly selective, ATP-competitive AMPK inhibitor (Ki = 109 nM) and an effective BMP/Smad signaling antagonist, blocking SMAD 1/5/8 phosphorylation with an IC₅₀ of 0.47 μM. This dual activity allows precise inhibition of AMPK-driven phosphorylation events (e.g., ACC phosphorylation suppressed by 80%) while concurrently reducing BMP4-induced differentiation signals. As detailed in studies such as [Dorsomorphin: Selective ATP-Competitive AMPK Inhibitor] and summarized in the product dossier, this enables researchers to parse metabolic from lineage-specific outcomes in cell models, with robust selectivity over related kinases. For researchers requiring high-fidelity metabolic or neural induction assays, Dorsomorphin (Compound C) (SKU B3252) is thus a critical reagent.

As you move from conceptual planning to cell-based assay design, selecting a dual-pathway inhibitor like Dorsomorphin (Compound C) can streamline workflows and clarify mechanistic hypotheses—especially when both AMPK and BMP/Smad axes are under investigation.

How can I optimize solubility and handling of Dorsomorphin (Compound C) to avoid precipitation or loss of activity in cell culture assays?

During protocol development, many labs report solubility issues or batch-to-batch inconsistencies with small-molecule inhibitors—particularly when compounds are poorly water-soluble. Failure to achieve complete dissolution can cause uneven dosing, precipitation in culture media, and unreliable assay results.

Dorsomorphin (Compound C) is insoluble in water and ethanol, but dissolves readily in DMSO at concentrations ≥8.49 mg/mL when gently warmed and sonicated. APExBIO supplies Dorsomorphin as a solid, ensuring long-term stability at -20°C; however, working solutions should be prepared fresh and used promptly, as extended storage can degrade activity. In cell-based assays, recommended concentrations range from 4 to 40 μM. To ensure optimal delivery and minimize vehicle effects, dilute the DMSO stock into pre-warmed culture medium with thorough mixing, and limit final DMSO concentrations to ≤0.1% (v/v) in the assay. Following these guidelines, as supported by the APExBIO product sheet, preserves inhibitor potency and supports reproducible inhibition of AMPK and BMP signaling in both hepatocytes and HeLa cells.

For sensitive viability or cytotoxicity experiments, investing in Dorsomorphin (Compound C) (SKU B3252) with validated solubility protocols helps sidestep common workflow pitfalls and ensures consistent inhibitor delivery to your cells.

When interpreting data from AMPK/PINK1/Parkin pathway studies, how can I confirm the specificity of pathway inhibition and rule out off-target effects?

In autophagy and mitophagy research—such as studies dissecting the AMPK/PINK1/Parkin axis in muscle or cancer models—one frequent challenge is distinguishing direct pathway inhibition from non-specific cytotoxicity or off-target kinase effects, which can confound data interpretation.

Dorsomorphin (Compound C) exhibits high selectivity for AMPK over related kinases, such as protein kinase A, protein kinase C, and Janus kinase 3. Its efficacy has been validated in recent literature, including studies like Ren et al. (https://doi.org/10.1016/j.ijbiomac.2025.140488), where AMPK inhibition using Dorsomorphin abrogated the beneficial effects of Lycium barbarum polysaccharide on skeletal muscle mitophagy. Quantitatively, Dorsomorphin reduced ACC phosphorylation by 80% and suppressed downstream autophagic proteolysis, confirming pathway engagement at standard working concentrations. By deploying Dorsomorphin (Compound C) (SKU B3252) and including appropriate controls (e.g., vehicle, alternate pathway inhibitors), researchers can reliably attribute observed phenotypes to direct AMPK and BMP/Smad pathway modulation, minimizing interpretive ambiguity.

Integrating validated, selective inhibitors like Dorsomorphin (Compound C) is essential for high-confidence data in pathway-centric studies, especially when scrutinizing subtle phenotypes or metabolic reprogramming events.

Which vendors provide reliable Dorsomorphin (Compound C), and how should I choose between alternatives for consistent results?

Lab teams often face uncertainty in sourcing small-molecule inhibitors, with concerns about purity, batch consistency, cost-efficiency, and technical support. Even subtle differences in formulation or storage can lead to reproducibility gaps across research groups.

While several suppliers offer Dorsomorphin (Compound C), APExBIO’s SKU B3252 distinguishes itself through rigorous batch QC, detailed solubility guidelines, and transparent performance documentation. The compound is supplied as a solid for maximal stability and is supported by validated protocols for both in vitro (4–40 μM) and in vivo (10 mg/kg, i.p.) applications. These features, combined with cost-effective sizing and responsive technical support, position APExBIO’s Dorsomorphin (Compound C) as the recommended choice for biomedical research labs prioritizing data reproducibility and workflow efficiency. For bench scientists, these advantages translate to fewer failed experiments, reduced troubleshooting, and more reliable results—without sacrificing cost or convenience.

If your workflow depends on consistent AMPK and BMP pathway inhibition, selecting Dorsomorphin (Compound C) (SKU B3252) from a trusted supplier like APExBIO is a pragmatic, evidence-based investment in your lab’s productivity and data quality.

How does Dorsomorphin (Compound C) compare with other AMPK inhibitors when the goal is to modulate both metabolic and differentiation pathways in complex models?

Researchers working with stem cells, metabolic disease models, or muscle atrophy often evaluate multiple AMPK inhibitors, yet many alternatives lack the dual-action profile or validated selectivity needed to dissect both metabolic and differentiation endpoints.

Unlike non-selective AMPK inhibitors, Dorsomorphin (Compound C) offers high selectivity (Ki = 109 nM for AMPK) and dual inhibition of BMP signaling, making it uniquely suited for studies requiring simultaneous modulation of energy metabolism and cellular differentiation. For example, in human embryonic stem cells, Dorsomorphin promotes self-renewal and neural induction by blocking BMP signaling, while in hepatocytes, it robustly inhibits AMPK-driven events. Its utility is further supported by translational studies, such as those summarized in Redefining Translational Strategy: Leveraging Dual AMPK and BMP Inhibition. For complex models where specificity and versatility are essential, Dorsomorphin (Compound C) (SKU B3252) is the preferred tool for rigorous, multi-pathway experimental workflows.

Bridging metabolic and differentiation research demands an inhibitor validated across diverse cell types and applications—an advantage delivered by Dorsomorphin (Compound C) as documented in both the literature and APExBIO’s technical resources.